Articles Healthcare | Healthcare Insights

top of page

HEALTHCARE INSIGHTS

Healthcare Insights

Healthcare Insights

HEALTHCARE INSIGHTS

Balancing Regulatory Standards with the Need for Rare Disease Innovation

Balancing Regulatory Standards with the Need for Rare Disease Innovation

The FDA's Flexibility Problem: When Rigor Becomes Risk

Apr 285 min read

Why Eli Lilly paid a massive premium for Centessa's narcolepsy platform and what it signals for the future of neuro-biotech M&A.

Why Eli Lilly paid a massive premium for Centessa's narcolepsy platform and what it signals for the future of neuro-biotech M&A.

Lilly's $6.3B Neuro Bet Isn't on a Drug, It's on a Biological Switch

Apr 96 min read

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

Apr 15 min read

Inside the Brewing $17.5B Bidding War for Abivax

Inside the Brewing $17.5B Bidding War for Abivax

Inside the Brewing $17.5B Bidding War for Abivax

Mar 237 min read

A nearly billion-dollar wave of investment from two pharma titans reveals a fierce new competition to control the future of drug discovery in South Korea.

A nearly billion-dollar wave of investment from two pharma titans reveals a fierce new competition to control the future of drug discovery in South Korea.

Pharma's New Center of Gravity Isn't Boston - It's Seoul.

Mar 184 min read

Pharma's Next Frontier Isn't a Drug

Pharma's Next Frontier Isn't a Drug

Pharma's Next Frontier Isn't a Drug

Mar 134 min read

Psilocybin-assisted therapy represents a radical departure from chronic symptom management, signaling a new era of acute, curative-intent interventions in psychiatry.

Psilocybin-assisted therapy represents a radical departure from chronic symptom management, signaling a new era of acute, curative-intent interventions in psychiatry.

The End of the Antidepressant As We Know It

Mar 63 min read

As ecological pressures mount in South Asia, a regional pathogen with a devastating mortality rate tests the limits of our pandemic-first preparedness model.

As ecological pressures mount in South Asia, a regional pathogen with a devastating mortality rate tests the limits of our pandemic-first preparedness model.

The Nipah Virus Returns with a 75% Fatality Rate No One Is Funding

Mar 24 min read

Why the Supreme Court’s latest decision changes the biopharma playbook, affects global supply chains, and questions Trump's executive leverage.

Why the Supreme Court’s latest decision changes the biopharma playbook, affects global supply chains, and questions Trump's executive leverage.

Supreme Court Reverses Trump's Tariffs, Crushes Trade Policy

Feb 265 min read

Why top scientists are now calling aging a treatable condition.

Why top scientists are now calling aging a treatable condition.

Age Reversal Is No Longer Science Fiction

Feb 245 min read

The removal of Paul Hudson and appointment of Garijo marks the beginning of a period of disciplined operational compression across Sanofi.

The removal of Paul Hudson and appointment of Garijo marks the beginning of a period of disciplined operational compression across Sanofi.

Sanofi's CEO Swap Defines the New Playbook for Big Pharma

Feb 205 min read

FDA’s Approvals in 2025 Favored Follow-Ons Over Breakthroughs

FDA’s Approvals in 2025 Favored Follow-Ons Over Breakthroughs

FDA’s Approvals in 2025 Favored Follow-Ons Over Breakthroughs

Feb 185 min read

Why TrumpRx Relies on Negotiation Rather Than Reform

Why TrumpRx Relies on Negotiation Rather Than Reform

Why TrumpRx Relies on Negotiation Rather Than Reform

Feb 167 min read

Novo Nordisk Sues HIMS Over 'Copycat' Ozempic

Novo Nordisk Sues HIMS Over 'Copycat' Ozempic

Novo Nordisk Sues HIMS Over 'Copycat' Ozempic

Feb 116 min read

AstraZeneca's $15 Billion Hedge Against Political Volatility

AstraZeneca's $15 Billion Hedge Against Political Volatility

AstraZeneca's $15 Billion Hedge Against Political Volatility

Feb 94 min read

10 Drugs Losing Exclusivity This Year

Feb 47 min read

Why Big Pharma is Suddenly Using Particle Physics to Target Cancer

Why Big Pharma is Suddenly Using Particle Physics to Target Cancer

Why Big Pharma is Suddenly Using Particle Physics to Target Cancer

Feb 25 min read

The Biopolitics of Deleting Chromosome 21

The Biopolitics of Deleting Chromosome 21

The Biopolitics of Deleting Chromosome 21

Jan 294 min read

Inside the Battle Over a Highly Controversial Antidepressant

Inside the Battle Over a Highly Controversial Antidepressant

Inside the Battle Over a Highly Controversial Antidepressant

Jan 264 min read

Biogen’s Neurology Transformation

Biogen’s Neurology Transformation

The Market is Mispricing Biogen’s Neurology Transformation

Jan 215 min read

Lilly & NVIDIA Are Building the 'Google' of Drug Discovery

Lilly & NVIDIA Are Building the 'Google' of Drug Discovery

Lilly & NVIDIA Are Building the 'Google' of Drug Discovery

Jan 195 min read

The Biotech CEO's Guide to Managing Trump

The Biotech CEO's Guide to Managing Trump

The Biotech CEO's Guide to Managing Trump

Jan 157 min read

Why One Drug is Redefining Everything from Cardiology to Addiction

Why One Drug is Redefining Everything from Cardiology to Addiction

Why One Drug is Redefining Everything from Cardiology to Addiction

Jan 135 min read

Viruses Designed by AI: A New Weapon Against Superbugs

Viruses Designed by AI: A New Weapon Against Superbugs

Viruses Designed by AI: A New Weapon Against Superbugs

Jan 84 min read

Sanofi Acquires Dynavax, Industrializes Vaccine Platform

Sanofi Acquires Dynavax, Industrializes Vaccine Platform

Sanofi Acquires Dynavax, Industrializes Vaccine Platform

Jan 24 min read

The Post-Needle Era: FDA Approves Novo Nordisk’s Weight-Loss Pill

The Post-Needle Era: FDA Approves Novo Nordisk’s Weight-Loss Pill

The Post-Needle Era: FDA Approves Novo Nordisk’s Weight-Loss Pill

Dec 30, 20255 min read

Artificial Stability: Can Subsidies Outpace the Rising Cost of Care?

Artificial Stability: Can Subsidies Outpace the Rising Cost of Care?

Artificial Stability: Can Subsidies Outpace the Rising Cost of Care?

Dec 29, 20254 min read

BIOSECURE Act: How Washington is Taking Over America's Labs

BIOSECURE Act: How Washington is Taking Over America's Labs

BIOSECURE Act: How Washington is Taking Over America's Labs

Dec 22, 20256 min read

Beyond Body Image: Medicalizing Teen Obesity with GLP-1s

Beyond Body Image: Medicalizing Teen Obesity with GLP-1s

Beyond Body Image: Medicalizing Teen Obesity with GLP-1s

Dec 16, 20253 min read

Neuralink Taps Top FDA Regulator to Steer Clinical Strategy

Neuralink Taps Top FDA Regulator to Steer Clinical Strategy

Neuralink Taps Top FDA Regulator to Steer Clinical Strategy

Dec 13, 20255 min read

Navigating 2026's Biopharma M&A Super-Cycle

Navigating 2026's Biopharma M&A Super-Cycle

Navigating 2026's Biopharma M&A Super-Cycle

Nov 14, 20258 min read

Beyond Patent Cliffs: M&A as a Lifeline for Buying Time, Not Growth

Beyond Patent Cliffs: M&A as a Lifeline for Buying Time, Not Growth

Beyond Patent Cliffs: M&A as a Lifeline for Buying Time, Not Growth

Oct 22, 20256 min read

Why Precision Medicine and Rare Disease Are Converging on a $50 Billion Frontier

Why Precision Medicine and Rare Disease Are Converging on a $50 Billion Frontier

Why Precision Medicine and Rare Disease Are Converging on a $50 Billion Frontier

Oct 17, 20254 min read

Beyond Chemo: How Pumitamig's Coordinated Strike Could Finally Treat SCLC

Beyond Chemo: How Pumitamig's Coordinated Strike Could Finally Treat SCLC

Beyond Chemo: How Pumitamig's Coordinated Strike Could Finally Treat SCLC

Sep 29, 20256 min read

A New Epidemic: The Alarming Rise of GI Cancers in Young Adults

A New Epidemic: The Alarming Rise of GI Cancers in Young Adults

A New Epidemic: The Alarming Rise of GI Cancers in Young Adults

Sep 12, 20255 min read

The Next-Gen COVID Vaccine: A Targeted Rollout for High-Risk Groups

The Next-Gen COVID Vaccine: A Targeted Rollout for High-Risk Groups

The Next-Gen COVID Vaccine: A Targeted Rollout for High-Risk Groups

Sep 3, 20254 min read

A New Wave of Capital is Revolutionizing Women’s Health

A New Wave of Capital is Revolutionizing Women’s Health

A New Wave of Capital is Revolutionizing Women’s Health

Aug 29, 20254 min read

Leukemia-on-a-Chip: A New Era for CAR T-Cell Therapy

Leukemia-on-a-Chip: A New Era for CAR T-Cell Therapy

Leukemia-on-a-Chip: A New Era for CAR T-Cell Therapy

Aug 27, 20254 min read

The New FDA: Navigating Politics and Public Skepticism

The New FDA: Navigating Politics and Public Skepticism

The New FDA: Navigating Politics and Public Skepticism

Aug 22, 20255 min read

Biopharma's Biggest Bets in 2025 Are All About M&A

Biopharma's Biggest Bets in 2025 Are All About M&A

Biopharma's Biggest Bets in 2025 Are All About M&A

Jul 11, 20257 min read

Beyond Weight Loss: Ozempic to Reshape Chronic Disease Care

Beyond Weight Loss: Ozempic to Reshape Chronic Disease Care

Beyond Weight Loss: Ozempic to Reshape Chronic Disease Care

Jul 3, 20254 min read

The 27-Hour Day Solved: AI is Finally Freeing Doctors from Documentation

The 27-Hour Day Solved: AI is Finally Freeing Doctors from Documentation

The 27-Hour Day Solved: AI is Finally Freeing Doctors from Documentation

Jul 2, 20254 min read

Women’s Brain Foundation Highlights $250 Billion Gap in Brain Health Equity

Women’s Brain Foundation Highlights $250 Billion Gap in Brain Health Equity

Women’s Brain Foundation Highlights $250 Billion Gap in Brain Health Equity

Jun 24, 20253 min read

Reverse Split, Forward Motion: Shuttle Pharma Plans to Fuel Cancer Innovation by Shrinking Shares

Jun 16, 20253 min read

Did the U.S. Undermine the Next Pandemic Vaccine?

Jun 13, 20254 min read

The global imperative to conquer cancer demands a continuous expansion of therapeutic options, pushing beyond traditional approaches to embrace novel science and strategic international collaboration.

The global imperative to conquer cancer demands a continuous expansion of therapeutic options, pushing beyond traditional approaches to embrace novel science and strategic international collaboration.

Immunotherapy's Next Chapter: Why Global Integration is Key to Expanding Cancer's Breakthroughs

Jun 12, 20255 min read

The $9 Billion Bet: Inside BMS and BioNTech's Bold Play to Redefine Solid Tumor Treatment

The $9 Billion Bet: Inside BMS and BioNTech's Bold Play to Redefine Solid Tumor Treatment

The $9 Billion Bet: Inside BMS and BioNTech's Bold Play to Redefine Solid Tumor Treatment

Jun 11, 20255 min read

The $16 Billion Algorithm: AI is Unlocking Pharma's Next Generation of Cures

The $16 Billion Algorithm: AI is Unlocking Pharma's Next Generation of Cures

The $16 Billion Algorithm: AI is Unlocking Pharma's Next Generation of Cures

Jun 9, 20255 min read

The Global Expansion of Clinical Trials: A Mid-Year Check-In On The Strategic Shift

The Global Expansion of Clinical Trials: A Mid-Year Check-In On The Strategic Shift

Beyond Borders: The Silent Revolution Reshaping Clinical Trials

Jun 3, 20255 min read

Why Novo Nordisk's CagriSema Success Still Crashed on Wall Street

Why Novo Nordisk's CagriSema Success Still Crashed on Wall Street

Why Novo Nordisk's CagriSema Success Still Crashed on Wall Street

May 30, 20255 min read

bottom of page